These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 3258432

  • 1. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
    Mizukawa K, Ogawa N, Sora YH.
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV, Kucherianu VG, Kudrin VS, Zhigal'tsev IV, Nikushkin EV, Sandalov IuG, Kaplun AP, Shvets VI.
    Biull Eksp Biol Med; 1997 Feb; 123(2):150-3. PubMed ID: 9280483
    [No Abstract] [Full Text] [Related]

  • 4. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Feb; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 5. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 6. Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
    Fujitake J, Kuno S, Mizuta E.
    Adv Neurol; 1990 Mar; 53():225-9. PubMed ID: 2239462
    [No Abstract] [Full Text] [Related]

  • 7. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
    Averkin RG, Korshunov VA, Shchegolevskiĭ NV, Mats VN, Markevich VA, Grigor'ian GA, Bazian AS.
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2010 Mar; 60(1):109-19. PubMed ID: 20352690
    [Abstract] [Full Text] [Related]

  • 8. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL, Hashim A, Lajtha A, Sershen H.
    J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
    [Abstract] [Full Text] [Related]

  • 9. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y.
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [Abstract] [Full Text] [Related]

  • 10. Reduction of muscarinic cholinergic receptors in mouse striatum by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its recovery by levodopa treatment.
    Ogawa N, Sora YH, Sato H, Mizukawa K.
    Res Commun Chem Pathol Pharmacol; 1987 Jul; 57(1):133-6. PubMed ID: 3499644
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG, Kryzhanovskiĭ GN, Kudrin VS, Iurasov VV, Nikushkin EV, Zhigal'tsev IV.
    Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
    [No Abstract] [Full Text] [Related]

  • 13. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
    Guttman M, Yong VW, Kim SU, Calne DB, Martin WR, Adam MJ, Ruth TJ.
    Synapse; 1988 May; 2(5):469-73. PubMed ID: 3263709
    [Abstract] [Full Text] [Related]

  • 14. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
    Goshima Y, Misu Y, Arai N, Misugi K.
    Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
    [Abstract] [Full Text] [Related]

  • 15. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M, Rojas P, Kravzov J, Rios C.
    Proc West Pharmacol Soc; 1993 Jan; 36():289-91. PubMed ID: 7690973
    [No Abstract] [Full Text] [Related]

  • 16. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN, Thakar JH, Grimes JD.
    Adv Neurol; 1990 Jan; 53():219-23. PubMed ID: 2239461
    [No Abstract] [Full Text] [Related]

  • 17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
    Rojas P, Altagracia M, Kravsov J, Rios C.
    Proc West Pharmacol Soc; 1992 Nov; 35():33-5. PubMed ID: 1502234
    [No Abstract] [Full Text] [Related]

  • 20. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
    Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y.
    Eur Neurol; 1987 Nov; 26 Suppl 1():16-23. PubMed ID: 2884111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.